ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for charts Cadastre-se para gráficos em tempo real, ferramentas de análise e preços.

MBRX Moleculin Biotech Inc

4,35
0,00 (0,00%)
Pré-mercado
Última atualização: 08:14:17
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Moleculin Biotech Inc MBRX NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,00 0,00% 4,35 08:14:17
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
4,35
mais cotações »

Notícias Recentes

Data Hora Fonte Título
18/04/202409:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
10/04/202409:30PRNUSMoleculin Announces Presentation of Positive Data..
28/03/202411:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
27/03/202410:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
27/03/202410:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
25/03/202408:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
22/03/202417:05PRNUSMoleculin Reports Full Year 2023 Financial Results
20/03/202408:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
20/03/202408:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19/03/202417:30PRNUSMoleculin Announces Reverse Stock Split
12/03/202410:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
24/01/202410:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
20/12/202323:16PRNUSMoleculin Announces Pricing of $4.5 Million Registered..
11/12/202310:50PRNUSMoleculin Presents Positive Interim Data from Phase 1B/2..
13/11/202310:05PRNUSMoleculin Announces Positive Interim Data in Annamycin..
13/11/202310:00PRNUSMoleculin Reports Third Quarter 2023 Financial Results
07/11/202310:45PRNUSMoleculin to Report Third Quarter Financial Results on..
06/11/202310:35PRNUSMoleculin Presents Positive Preliminary Efficacy Findings..
11/10/202310:05PRNUSMoleculin to Participate in the Virtual Investor Ask the CEO..
02/10/202309:40PRNUSMoleculin Doses First Subjects in Phase 2 Portion of..
21/09/202309:50PRNUSMoleculin Announces Completion of Enrollment in U.S. Phase..
18/09/202309:40PRNUSMoleculin Announces New Positive Independent Report of No..
14/09/202309:35PRNUSMoleculin Announces Abstract Accepted for Poster..
05/09/202309:35PRNUSMoleculin to Present at the H.C. Wainwright 25th Annual..
11/08/202307:45PRNUSMoleculin Reports Second Quarter 2023 Financial Results
10/08/202317:05PRNUSMoleculin Provides Update on Ongoing Clinical Trials and..
07/08/202309:40PRNUSMoleculin Retains Shareholder Intelligence Services, LLC to..
03/08/202309:45PRNUSMoleculin to Report Second Quarter Financial Results on..
13/07/202309:40PRNUSMoleculin Announces Publication of Data from Successful..
06/07/202309:45PRNUSMoleculin to Participate in the Virtual Investor Summer..
13/06/202309:35PRNUSMoleculin to Participate in the Healthcare Virtual..
30/05/202310:05PRNUSMoleculin Announces Adjournment of 2023 Annual Meeting to..
11/05/202308:05PRNUSMoleculin Reports First Quarter 2023 Financial Results
10/05/202317:05PRNUSMoleculin Provides Update on Ongoing Clinical Trials and..
04/05/202309:35PRNUSMoleculin to Report First Quarter Financial Results on May..
02/05/202309:35PRNUSMoleculin Successfully Completes First Cohort in Phase 1b/2..

Seu Histórico Recente

Delayed Upgrade Clock